VNDA - US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug Hetlioz | Benzinga
The U.S. Supreme Court has reportedly chosen not to review Vanda Pharmaceuticals Inc’s (NASDAQ:VNDA) attempt to revive patents for its sleep-disorder medication Hetlioz, which had previously been invalidated in a legal battle with generic drugmakers Teva Pharmaceutical Industries Limited (NYSE:TEVA) and Apotex.
Vanda had filed a lawsuit in 2018 against Teva and Apotex in Delaware, alleging patent infringement after they sought approval to manufacture generic versions of Hetlioz, Reuters noted.
The Federal Circuit, a patent-focused court, ruled against Vanda, leading to the company’s appeal to the Supreme Court, which was declined.
Also Read: Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak’s Takeover ...